A landmark trial of more than 17,600 overweight and obese patients with cardiovascular disease (but not diabetes), found that semaglutide reduced their risk of serious cardiovascular events by 20%
New England Journal of Medicine, 389 (6), 514526
That adverse event profile is not on the TRIUMPH-1 topline safety sheet
You might conclude that the compound is ineffective at a certain concentration when, in reality, you were never administering that concentration to begin with
However, limited or no medical nutrition therapy (MNT) guidelines are provided to healthcare providers and patients regarding adequate nutrient intake during GLP-1RA use
01Subtle appetite recalibration without aggressive suppression 02Body-composition focus lean preservation over scale chasing 03Pairs cleanly with longevity, recovery, and hormone protocols 01Lower-dose receptor activation The same GLP-1 receptor pathway is engaged, at a dose calibrated for refinement rather than aggressive suppression
